Phenethylamine

Phenethylamine (PEA) is a naturally occurring trace monoamine alkaloid found endogenously in the human brain and in foods such as chocolate, acting primarily as a releaser of catecholamines including dopamine and norepinephrine. It functions as a trace amine-associated receptor 1 (TAAR1) agonist, though its rapid monoamine oxidase B (MAO-B) metabolism severely limits its pharmacological duration in vivo.

Origin & History

Phenethylamine (PEA) is a naturally occurring aromatic amine and trace amine neurotransmitter with the chemical formula C₈H₁₁N. It is endogenously produced in the human body and found in certain plants and foods, appearing as a colorless liquid at room temperature that is soluble in water, ethanol, and ether.

Historical & Cultural Context

No historical context or uses in traditional medicine systems are described in the available research sources. The compound's traditional applications, if any, are not documented.

Health Benefits

• No clinically proven health benefits - no human clinical trials identified in available research
• Potential neurotransmitter activity - acts as a trace amine but pharmacological actions listed as unknown
• Possible 5-HT2A receptor binding - DrugBank notes potential interaction but without clinical evidence
• May influence serine protease activity - suggested activity against PRSS1 substrates but not clinically validated
• High oral bioavailability predicted - computational models suggest bioavailability rating of 1 (high) based on chemical properties

How It Works

Phenethylamine acts as an agonist at trace amine-associated receptor 1 (TAAR1), triggering the release of dopamine, norepinephrine, and serotonin from presynaptic nerve terminals. It is rapidly degraded by monoamine oxidase B (MAO-B) with a plasma half-life of approximately 5–10 minutes, which severely curtails central nervous system exposure after oral ingestion. DrugBank also notes potential binding activity at the 5-HT2A serotonin receptor, though the clinical significance of this interaction has not been established in controlled human studies.

Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses for phenethylamine were identified in the available research sources. DrugBank notes unknown pharmacological actions with only potential binding targets suggested, and no PubMed PMIDs are available for phenethylamine-specific clinical studies.

Clinical Summary

No published randomized controlled trials have evaluated phenethylamine supplementation for any health outcome in human populations, making definitive efficacy claims unsupported by current evidence. One small, older study (Fischer et al., 1968) observed elevated urinary PEA excretion in subjects experiencing heightened mood states, suggesting an endogenous correlative role rather than a therapeutic one. Animal model research has demonstrated dopaminergic and noradrenergic activity, but these findings have not been translated into validated human clinical outcomes. The overall evidence base is preclinical and observational, and no regulatory body has approved PEA for any medical indication.

Nutritional Profile

Phenethylamine (PEA) is a biogenic amine and trace amine compound, not a conventional nutrient, and therefore lacks a traditional macronutrient or micronutrient profile. Molecular formula: C8H11N, molecular weight: 121.18 g/mol. It is a low-molecular-weight monoamine alkaloid structurally analogous to amphetamine. Not a source of protein, carbohydrates, fats, fiber, vitamins, or minerals in any nutritionally meaningful quantity. As a bioactive compound, it occurs endogenously in the human brain at trace concentrations (approximately 0.1–1.0 µg/g brain tissue). Dietary sources include fermented foods, chocolate (cocoa contains approximately 0.1–0.7 µg/g), aged cheeses, and certain fermented beverages, though concentrations are low and variable. Oral bioavailability is considered poor due to rapid first-pass metabolism by monoamine oxidase B (MAO-B) in the gut and liver, resulting in a very short plasma half-life (estimated under 5–10 minutes in most individuals). Primary metabolite is phenylacetic acid, formed via MAO-B oxidative deamination. Co-administration with MAO inhibitors significantly extends its half-life and systemic activity. No established Dietary Reference Intake (DRI) or Recommended Daily Allowance (RDA) exists. Not classified as an essential nutrient.

Preparation & Dosage

No clinically studied dosage ranges are reported for any forms of phenethylamine (extract, powder, or standardized), as human clinical trials are absent from available sources. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified in research

Safety & Interactions

Phenethylamine may cause adverse effects including increased heart rate, elevated blood pressure, headache, and anxiety, particularly at higher doses, due to its catecholamine-releasing properties. Co-administration with monoamine oxidase inhibitors (MAOIs) such as phenelzine or selegiline poses a serious interaction risk, as MAO-B inhibition dramatically extends PEA's half-life and can precipitate hypertensive crisis or serotonin syndrome. Individuals with cardiovascular disease, hypertension, bipolar disorder, or schizophrenia should avoid PEA supplementation given its stimulant-like and potentially psychoactive profile. Safety data during pregnancy and lactation are absent, and use is not recommended in these populations.